Molecular Response

Crown is acquiring Molecular Response's existing PDX models and 8,000 viable human tumors for model development.

NEW YORK (GenomeWeb) – Therapeutic research firm Boston Strategics and molecular diagnostic services shop Molecular Response have agreed to design and manage drug development programs together with the aim of identifying subpopulations of best responders to treatments and improving their probabil

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Transparent and Molecular Response today announced the extension of validation studies and the execution of a long-term collaboration agreement.

By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Gen-Probe disclosed in its annual 2011 earnings document that it has lost almost $41 million in its investment in Pacific Biosciences as of the end of 2011.

Pharmaceutical firm SuperGen will have limited access to Molecular Response's "living" cell bank of primary tumor cells, high-content imaging, and molecular characterization platforms.

The R&D deal targets oncology and cardiovascular disease.

The bank, formerly owned by Oncotech, contains more than 144,000 discrete cancer samples.

People in the News

Premium

David Ledbetter, Thomas Broudy

People in the News

Premium

RainDance taps Richard Lussier and Ingrid Choupin for sales positions; Molecular Response hires Thomas Broudy as chief scientific officer and Richard Scuderi as medical director.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.